The Latin America, Middle East and Africa Smart Inhalers Market is expected to witness market growth of 30.5% CAGR during the forecast period (2021 2027).
Smart inhalers, based on the time of the last dose, notify patients of missed or repeated doses and remind them to take their doses on time, simply and automatically. These reminders can be sent to the patient wherever he or she is. These gadgets can help ease the stress of remembering to take prescriptions on time, especially if there are a lot of medications to remember. They can aid in the improvement of breathing techniques and efficacy. Finally, they keep track of symptoms for both patients and doctors to see how, where, and when symptoms worsen, as well as monitor the usage of the rescue inhaler for quick relief.
The crucial issue here is that a patient's poor control be recognized, as evidenced by the requirement of rescue or reliever medication more than twice a year. This highlights the need to scale up the preventive plan for such a person, such as retraining the patient to correctly use the inhaler or looking for trigger factors such as a new pet, tobacco smoke exposure, or airborne pollution. Smart inhalers can help expand the reach of specialist health care to remote or underserved areas, albeit adherence is generally poor. At all levels, such initiatives are also cost-effective.
There is inter-and intra-regional variation in asthma prevalence in the Middle East. The prevalence was reported to be 23.6 percent in Saudi Arabia, 19.8 percent in Qatar, and 7.8 percent to 17.3 percent in different parts of Oman. Using the ISAAC questionnaire, research from the UAE's Al in region found a prevalence of 13 percent, while another using the ECRHS questionnaire found a range of 8 to 10% across the UAE. Asthma has a detrimental effect on people's quality of life and contributes to the financial burden on individuals and the healthcare system. The cost of asthma medicine isn't the only factor to consider. Outpatient consultations, inpatient stays for illness control and missed work or school are all examples of hospital visits that incur additional costs. According to the AIRGNE data, asthma causes sickness absenteeism in 30 percent of adults and 52 percent of children each year. The adoption of smart inhalers in the region can empower
The Brazil market dominated the LAMEA Smart Inhalers Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $7,116.9 Thousands by 2027. The Argentina market is anticipated to grow at a CAGR of 31.2% during (2021 - 2027). Additionally, The UAE market is expected to display a CAGR of 30.1% during (2021 - 2027).
Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
Smart inhalers, based on the time of the last dose, notify patients of missed or repeated doses and remind them to take their doses on time, simply and automatically. These reminders can be sent to the patient wherever he or she is. These gadgets can help ease the stress of remembering to take prescriptions on time, especially if there are a lot of medications to remember. They can aid in the improvement of breathing techniques and efficacy. Finally, they keep track of symptoms for both patients and doctors to see how, where, and when symptoms worsen, as well as monitor the usage of the rescue inhaler for quick relief.
The crucial issue here is that a patient's poor control be recognized, as evidenced by the requirement of rescue or reliever medication more than twice a year. This highlights the need to scale up the preventive plan for such a person, such as retraining the patient to correctly use the inhaler or looking for trigger factors such as a new pet, tobacco smoke exposure, or airborne pollution. Smart inhalers can help expand the reach of specialist health care to remote or underserved areas, albeit adherence is generally poor. At all levels, such initiatives are also cost-effective.
There is inter-and intra-regional variation in asthma prevalence in the Middle East. The prevalence was reported to be 23.6 percent in Saudi Arabia, 19.8 percent in Qatar, and 7.8 percent to 17.3 percent in different parts of Oman. Using the ISAAC questionnaire, research from the UAE's Al in region found a prevalence of 13 percent, while another using the ECRHS questionnaire found a range of 8 to 10% across the UAE. Asthma has a detrimental effect on people's quality of life and contributes to the financial burden on individuals and the healthcare system. The cost of asthma medicine isn't the only factor to consider. Outpatient consultations, inpatient stays for illness control and missed work or school are all examples of hospital visits that incur additional costs. According to the AIRGNE data, asthma causes sickness absenteeism in 30 percent of adults and 52 percent of children each year. The adoption of smart inhalers in the region can empower
The Brazil market dominated the LAMEA Smart Inhalers Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $7,116.9 Thousands by 2027. The Argentina market is anticipated to grow at a CAGR of 31.2% during (2021 - 2027). Additionally, The UAE market is expected to display a CAGR of 30.1% during (2021 - 2027).
Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Metered Dose Inhalers (MDI's)
- Dry Powdered Inhalers (DPIs)
By Disease Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, LLC
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health, Inc.
- Philip Morris International, Inc. (Vectura Group Plc)
- Resmed, Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd.
Unique Offerings from the publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Smart Inhalers Market by Product
Chapter 5. LAMEA Smart Inhalers Market by Disease Indication
Chapter 6. LAMEA Smart Inhalers Market by Distribution Channel
Chapter 7. LAMEA Smart Inhalers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, LLC
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health, Inc.
- Philip Morris International, Inc. (Vectura Group Plc)
- Resmed, Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
